Michael Kelly, PhD

Title: Chief Scientific Advisor

Organization: CureDuchenne

Bio: Michael Kelly, PhD is a senior pharmaceutical executive and brings more than 30 years of experience in drug discovery and development to the organization. As CureDuchenne’s Chief Scientific Advisor, he is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.

Next Generation Technology Panel

A brief overview of the rationale behind next generation technology, as well as presentations from the companies in this space. Moderated discussion included.

Erin Brubaker

Chief Operating Officer

Code Bio

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Joe McIntosh, MD

Chief Medical Officer

Gennao Bio

See more from same speaker

Genine Winslow, MSc

CEO & President

Chameleon Biosciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years